Reports
Asia Pacific Drug Development Market Size, Growth, Forecast: By Mode: In House, Outsourced; By Process Step: Process Research Development, Formulation, Analytical and Stability Studies, Drug Metabolism and Pharmacokinetics (DMPK), Packaging, Others; By Therapeutic Area; Regional Analysis; Competitive Landscape; 2024-2032
Asia Pacific Drug Development Market Outlook
The Asia Pacific drug development market reached USD 46.96 billion in 2023 and is projected to grow at a CAGR of 7.1% over the 2024-2032 forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The changing market dynamics, such as the constant growth of the pharmerging market, coupled with the saturated growth rates in established markets, are driving the growth of the drug development market in the Asia Pacific. Also, capital inflows from the western region in the Asian pharmaceutical industry offer substantial opportunities for business expansion to new entrants.
Market Segmentation
Drug development is the method of developing a new drug once a lead compound has been discovered through the drug discovery method. The Asia Pacific drug development industry can be divided on the basis of segments like mode, process step, and therapeutic area.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The industry can be broadly categorised based on mode into:
- In House
- Outsourced
The industry can be divided on the basis of process step as:
- Process Research Development
- Formulation
- Analytical and Stability Studies
- Drug Metabolism and Pharmacokinetics (DMPK)
- Safety Assessment (Toxicology)
- Regulatory Compliance
- Packaging
The industry can be divided based on the therapeutic area:
- Oncology
- Inflammation and Immunology
- Cardiology
- Neuroscience
- Others
The EMR report looks into the Asia Pacific drug development markets like India, Japan, and China.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
Regulatory authorities such as the China Food and Drug Administration have made significant improvements in addressing critical system gaps. These are working to provide the basis for enhancing the registration process and driving developments in the drug development market in the Asia Pacific in order to stimulate growth. In the clinical trials, companies have efficiently shifted from giving a value proposition based on "speed and cost" to value-added proposals. It involves the transition from early-stage licensing to later stage licensing for growth. However, the trend for business model charges, as well as risk-sharing and collaborations, are being adopted. The rise in new product launches depicts the remarkable growth within the Asia Pacific drug development industry. The cost-saving advantages of the Asian market have prompted global companies to integrate Asia into its global framework for drug development. However, to some degree, the existence of some constraints in the area is anticipated to hinder growth. One of these problems is that the study promoters have to pay the cost of studies and research in Asia, whereas insurance providers and government payers in the western countries make payments throughout the trial for the general healthcare costs of enrolled patients. Nevertheless, the average cost of running studies in the Asia Pacific is significantly lower than in the West, thus, reducing the impact of this constraint.
Competitive Landscape
The report presents a detailed analysis of the following key players in the Asia Pacific drug development market, looking into their capacity, competitive landscape, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Samsung Biologics
- WuXi Biologics
- Celltrion Inc.
- PT Kalbe Farma Tbk.
- Eurofins Advinus
- Labcorp Drug Development
- Others
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter's Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2018-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Mode, Process Step, Therapeutic Area, Region |
| Breakup by Mode | In House, Outsourced |
| Breakup by Process Step | Process Research Development, Formulation, Analytical and Stability Studies, Drug Metabolism and Pharmacokinetics (DMPK), Safety Assessment (Toxicology), Regulatory Compliance, Packaging |
| Breakup by Therapeutic Area | Oncology, Inflammation and Immunology, Cardiology, Neuroscience, Others |
| Breakup by Region | China, Japan, India |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Samsung Biologics, WuXi Biologics, Celltrion Inc., PT Kalbe Farma Tbk., Eurofins Advinus, Labcorp Drug Development, Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Asia Pacific
7 Opportunities and Challenges in the Market
8 Asia Pacific Drug Development Market Analysis
8.1 Key Industry Highlights
8.2 Asia Pacific Drug Development Historical Market (2018-2023)
8.3 Asia Pacific Drug Development Market Forecast (2024-2032)
8.4 Asia Pacific Drug Development Market by Mode
8.4.1 In House
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2023)
8.4.1.3 Forecast Trend (2024-2032)
8.4.2 Outsourced
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2023)
8.4.2.3 Forecast Trend (2024-2032)
8.5 Asia Pacific Drug Development Market by Process Step
8.5.1 Process Research Development
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2023)
8.5.1.3 Forecast Trend (2024-2032)
8.5.2 Formulation
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2023)
8.5.2.3 Forecast Trend (2024-2032)
8.5.3 Analytical and Stability Studies
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2018-2023)
8.5.3.3 Forecast Trend (2024-2032)
8.5.4 Drug Metabolism and Pharmacokinetics (DMPK)
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2018-2023)
8.5.4.3 Forecast Trend (2024-2032)
8.5.5 Safety Assessment (Toxicology)
8.5.5.1 Market Share
8.5.5.2 Historical Trend (2018-2023)
8.5.5.3 Forecast Trend (2024-2032)
8.5.6 Regulatory Compliance
8.5.6.1 Market Share
8.5.6.2 Historical Trend (2018-2023)
8.5.6.3 Forecast Trend (2024-2032)
8.5.7 Packaging
8.5.7.1 Market Share
8.5.7.2 Historical Trend (2018-2023)
8.5.7.3 Forecast Trend (2024-2032)
8.6 Asia Pacific Drug Development Market by Therapeutic Area
8.6.1 Oncology
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2018-2023)
8.6.1.3 Forecast Trend (2024-2032)
8.6.2 Inflammation and Immunology
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2018-2023)
8.6.2.3 Forecast Trend (2024-2032)
8.6.3 Cardiology
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2018-2023)
8.6.3.3 Forecast Trend (2024-2032)
8.6.4 Neuroscience
8.6.4.1 Market Share
8.6.4.2 Historical Trend (2018-2023)
8.6.4.3 Forecast Trend (2024-2032)
8.6.5 Others
8.7 Asia Pacific Drug Development Market by Region
8.7.1 Market Share
8.7.1.1 China
8.7.1.2 Japan
8.7.1.3 India
9 Regional Analysis
9.1 China
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Japan
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
9.3 India
9.3.1 Historical Trend (2018-2023)
9.3.2 Forecast Trend (2024-2032)
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 Samsung Biologics
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 WuXi Biologics
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 Celltrion Inc.
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 PT Kalbe Farma Tbk.
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 Eurofins Advinus
12.2.5.1 Company Overview
12.2.5.2 Product Portfolio
12.2.5.3 Demographic Reach and Achievements
12.2.5.4 Certifications
12.2.6 Labcorp Drug Development
12.2.6.1 Company Overview
12.2.6.2 Product Portfolio
12.2.6.3 Demographic Reach and Achievements
12.2.6.4 Certifications
12.2.7 Others
13 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Asia Pacific Drug Development Market: Key Industry Highlights, 2018 and 2032
2. Asia Pacific Drug Development Historical Market: Breakup by Mode (USD Billion), 2018-2023
3. Asia Pacific Drug Development Market Forecast: Breakup by Mode (USD Billion), 2024-2032
4. Asia Pacific Drug Development Historical Market: Breakup by Process Step (USD Billion), 2018-2023
5. Asia Pacific Drug Development Market Forecast: Breakup by Process Step (USD Billion), 2024-2032
6. Asia Pacific Drug Development Historical Market: Breakup by Therapeutic Area (USD Billion), 2018-2023
7. Asia Pacific Drug Development Market Forecast: Breakup by Therapeutic Area (USD Billion), 2024-2032
8. Asia Pacific Drug Development Historical Market: Breakup by Region (USD Billion), 2018-2023
9. Asia Pacific Drug Development Market Forecast: Breakup by Region (USD Billion), 2024-2032
10. Asia Pacific Drug Development Market Structure
Key Questions Answered in the Report
In 2023, the Asia Pacific drug development market attained a value of nearly USD 46.96 billion.
The market is projected to grow at a CAGR of 7.1% between 2024 and 2032.
The major drivers of the industry include rising population, substantial opportunities for business expansion, lower costs in Asia and improving registration processes.
The constant growth of the pharmaceutical market, coupled with the saturated growth rates in established markets, is expected to be a key trend guiding the growth of the industry.
The types of drug development available are in house and outsourced.
Drug development can have different process steps like process research development, formulation, analytical and stability studies, drug metabolism and pharmacokinetics (DMPK), safety assessment (toxicology), regulatory compliance and packaging.
Oncology, inflammation and immunology, cardiology, and neuroscience, amongst others are some therapeutic areas for the drug development market.
The leading players in this market are Samsung Biologics, WuXi Biologics, Celltrion Inc., PT Kalbe Farma Tbk., Eurofins Advinus, and Labcorp Drug Development, among others.
Analyst Review
The Asia Pacific drug development market attained a value of USD 46.96 billion in 2023, driven by the substantial opportunities for business expansion and the lower costs in Asia and improving registration processes. The market is expected to witness a further growth in the forecast period of 2024-2032, growing at a CAGR of 7.1%.
EMR’s meticulous research methodology delves deep into the industry, covering the macro and micro aspects of the industry. Based on the mode of deployment, the drug development market can be segmented into in house and outsourced. By process step, the industry can be divided into process research development, formulation, analytical and stability studies, drug metabolism and pharmacokinetics (DMPK), safety assessment (Toxicology), regulatory compliance and packaging. Oncology, inflammation and immunology, cardiology, and neuroscience, amongst others are some therapeutic areas for the drug development market. The key players in the above industry include Samsung Biologics, WuXi Biologics, Celltrion Inc., PT Kalbe Farma Tbk., Eurofins Advinus, and Labcorp Drug Development, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$2799
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER